These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 11972392

  • 1. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
    Ferrandina G, Ranelletti FO, Lauriola L, Fanfani F, Legge F, Mottolese M, Nicotra MR, Natali PG, Zakut VH, Scambia G.
    Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
    [Abstract] [Full Text] [Related]

  • 2. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
    Raspollini MR, Susini T, Amunni G, Paglierani M, Taddei A, Marchionni M, Scarselli G, Taddei GL.
    Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
    [Abstract] [Full Text] [Related]

  • 3. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
    Ferrandina G, Ranelletti FO, Gallotta V, Martinelli E, Zannoni GF, Gessi M, Scambia G.
    Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
    [Abstract] [Full Text] [Related]

  • 4. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
    Ali-Fehmi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD, Munkarah AR.
    Cancer; 2003 Oct 01; 98(7):1423-9. PubMed ID: 14508829
    [Abstract] [Full Text] [Related]

  • 5. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
    Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, Yu D, Pollock RE, Baker L.
    Cancer; 2005 Feb 15; 103(4):830-8. PubMed ID: 15641030
    [Abstract] [Full Text] [Related]

  • 6. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer.
    Seo SS, Song YS, Kang DH, Park IA, Bang YJ, Kang SB, Lee HP.
    Gynecol Oncol; 2004 Mar 15; 92(3):927-35. PubMed ID: 14984962
    [Abstract] [Full Text] [Related]

  • 7. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
    Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2002 Nov 15; 8(11):3438-44. PubMed ID: 12429632
    [Abstract] [Full Text] [Related]

  • 8. Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer.
    Lanza-Jacoby S, Burd R, Rosato FE, McGuire K, Little J, Nougbilly N, Miller S.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6161-9. PubMed ID: 17062693
    [Abstract] [Full Text] [Related]

  • 9. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
    Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J.
    Gynecol Oncol; 2004 Oct 15; 95(1):89-94. PubMed ID: 15385115
    [Abstract] [Full Text] [Related]

  • 10. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
    Massard C, Voigt JJ, Laplanche A, Culine S, Lortholary A, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Fizazi K.
    Br J Cancer; 2007 Oct 08; 97(7):857-61. PubMed ID: 17876336
    [Abstract] [Full Text] [Related]

  • 11. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE, Pollice AA, Smith CA, Janocko LE, Sweeney L, Brown KA, Singh SG, Gu L, Yakulis R, Lucke JF.
    Clin Cancer Res; 1998 Apr 08; 4(4):913-28. PubMed ID: 9563885
    [Abstract] [Full Text] [Related]

  • 12. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W.
    Int J Radiat Oncol Biol Phys; 2005 Jun 01; 62(2):309-17. PubMed ID: 15890569
    [Abstract] [Full Text] [Related]

  • 13. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
    Kiyoshima K, Oda Y, Kinukawa N, Naito S, Tsuneyoshi M.
    Hum Pathol; 2005 May 01; 36(5):522-30. PubMed ID: 15948119
    [Abstract] [Full Text] [Related]

  • 14. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
    Milas I, Komaki R, Hachiya T, Bubb RS, Ro JY, Langford L, Sawaya R, Putnam JB, Allen P, Cox JD, McDonnell TJ, Brock W, Hong WK, Roth JA, Milas L.
    Clin Cancer Res; 2003 Mar 01; 9(3):1070-6. PubMed ID: 12631609
    [Abstract] [Full Text] [Related]

  • 15. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
    Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ.
    Cancer Res; 2002 Oct 01; 62(19):5405-7. PubMed ID: 12359744
    [Abstract] [Full Text] [Related]

  • 16. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, Rocca A, Peruzzotti G, Colleoni M.
    Cancer; 2007 Aug 01; 110(3):509-17. PubMed ID: 17559147
    [Abstract] [Full Text] [Related]

  • 17. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma.
    Lee EY, Cibull ML, Strodel WE, Haley JV.
    Arch Pathol Lab Med; 1994 Mar 01; 118(3):235-9. PubMed ID: 7907854
    [Abstract] [Full Text] [Related]

  • 18. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
    Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA.
    Cancer; 2005 Aug 15; 104(4):676-81. PubMed ID: 15981280
    [Abstract] [Full Text] [Related]

  • 19. Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.
    Jia RP, Xu LW, Su Q, Zhao JH, Li WC, Wang F, Xu Z.
    Asian J Androl; 2008 Sep 15; 10(5):758-64. PubMed ID: 18645679
    [Abstract] [Full Text] [Related]

  • 20. Cyclooxygenase-2 expression in borderline ovarian tumors.
    Ferrandina G, Zannoni GF, Ranelletti FO, Legge F, Gessi M, Salutari V, Gallotta V, Lauriola L, Scambia G.
    Gynecol Oncol; 2004 Oct 15; 95(1):46-51. PubMed ID: 15385109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.